-- Donation Supports Purchase of Vehicles to Assist Coolmine in
Providing Residential Services for Families Affected by Substance
Abuse --
-- Mallinckrodt Employees Offer More than 200 Volunteer Hours in
Support of Coolmine TC --
DUBLIN, Sept. 17, 2018
/PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global
specialty pharmaceutical company, today announced a donation to
Coolmine Therapeutic Community enabling the purchase of two new
transport vehicles for the centre.
Coolmine provides community, day and residential services to men
and women with problematic substance use and their families in
Ireland. On Monday,
Mallinckrodt President and Chief
Executive Officer Mark Trudeau
presented the keys to those transport vehicles to Coolmine CEO
Pauline McKeown.
"Mallinckrodt and Coolmine have had
a long-standing relationship, and Coolmine is recognized as a
leading corporate social responsibility (CSR) partner for us in
Dublin," Trudeau said. "We
are pleased to enable the purchase of the vehicles to help the
centre meet vital transportation needs in local residential
services. Mallinckrodt is committed to
strengthening the communities in which our employees live and work,
and our CSR activities strive to advance society in meaningful ways
such as this."
The new vehicles – replacing older, unreliable minibuses – will
provide transport for those served at Ashleigh House, which cares
for up to 24 women and 17 children from infants to those at
preschool age. Mothers and children at the facility can have
particular care and medical issues that result in numerous external
appointments on any given day. These include maternity, antenatal,
adult and children's hospital appointments, as well as general
practitioner visits. Many clients in both residential units require
transport for access visits and case conferences across
Ireland that help keep families
together.
Additionally, the vehicles will transport clients who are
mothers and fathers to educational and social family activities as
part of Coolmine's Parents under Pressure scheme. They will also be
utilised to accommodate transportation of clients attending day
services and step down programmes from community house settings who
may have childcare needs.
"Coolmine has benefitted from such a real and meaningful
corporate social responsibility partnership with Mallinckrodt for the past two years, and we are
deeply grateful," said McKeown. "This additional financial
support is significant, allowing us access to new vehicles that
will be vital for our support of clients and their families. We
would not be able to bolster our service without the company's
support. We are also appreciative of the volunteer hours provided
by Mallinckrodt staff, which have had a
lasting impact on Coolmine."
Mallinckrodt colleagues have
provided more than 200 volunteer hours assisting with upgrades of
Coolmine's premises, internally and externally, in addition to the
company's financial support.
"Coolmine Therapeutic Community provides critical support and
services for families and individuals encountering very serious
challenges in their lives," said Dr. David Keenan, Managing Director of Mallinckrodt
Pharmaceuticals Ireland. "On behalf of our Mallinckrodt employees in Ireland, we are very pleased to continue to
support the centre in its essential work."
ABOUT COOLMINE
Coolmine has been a national drug and
alcohol-treatment service provider in Ireland since 1973. We provide a range of high
quality residential and non-residential services to men, women,
their children and their families impacted by addiction. Our
specialist programmes work with the most marginalised in Irish
society. Coolmine is the only mother and child residential
rehabilitation service in Ireland,
catering for women with children – and pregnant women who are
seeking help with addiction.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops,
manufactures, markets and distributes specialty pharmaceutical
products and therapies. Areas of focus include autoimmune and rare
diseases in specialty areas like neurology, rheumatology,
nephrology, pulmonology and ophthalmology; immunotherapy and
neonatal respiratory critical care therapies; analgesics and
gastrointestinal products. Included within the company's
discontinued operations, the Specialty Generics business includes
specialty generic drugs and active pharmaceutical ingredients. To
learn more about Mallinckrodt, visit
www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission (SEC) disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
CONTACTS
Coolmine:
Aileen
Moon
Communications Officer
087 337 6665
Aileen.moon@coolminetc.ie
Mallinckrodt:
Media
Rhonda Sciarra
Senior Communications Manager
+1-908-238-6765
rhonda.sciarra@mnk.com
Meredith Fischer
Chief Public Affairs Officer
+1-908-997-9294
meredith.fischer@mnk.com
Investor Relations
Daniel J. Speciale, CPA
Investor Relations and Strategy Officer
+1-314-654-3638
daniel.speciale@mnk.com
Logo -
https://mma.prnewswire.com/media/167103/mallinckrodt_plc_logo.jpg
Logo -
https://mma.prnewswire.com/media/745187/Mallinckrodt_plc_Coolmine_Logo.jpg